BioWorld

Feb. 10, 2009

Lundbeck Gains U.S. Foothold in $900M Deal for Ovation

Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today) Read More

Investors Seeing Positive Side for Biotech in Bleak Economy

Panel: Keep Options Open to Survive Troubled Times

ViroPharma Shares Halved as Maribavir Fails Phase III Trial

Alliance Management Plays Important Role in Avoiding Failure

Lobbying Dynamics Reveal New Trends in Power

Gilded Age Can Be Ushered in by Biopartnered Gene Therapies

Corrections & Clarifications

Dynavax Soars on Possibility of Regulatory Path for Heplisav

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...